Oral oncology: Utilization of selected oral antineoplastic enzyme inhibitor agents

American Journal of Pharmacy Benefits

Volumn 4, Issue 4, 2012, Pages 178-182

  Theodorou, Anna A ^a   Palmieri, Anthony ^a   Szychowski, John A ^a   Sehman, Marina L ^a   Swarna, Vinod ^a  

^a CVS Caremark   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; DASATINIB; ERLOTINIB; IMATINIB; NILOTINIB; SORAFENIB; SUNITINIB;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADVANCED CANCER; ARTICLE; CHRONIC MYELOID LEUKEMIA; COHORT ANALYSIS; DEMOGRAPHY; DERMATOFIBROSARCOMA PROTUBERANS; DRUG COST; DRUG TOLERANCE; EOSINOPHILIC LEUKEMIA; GASTROINTESTINAL STROMAL TUMOR; GENE; GENE REARRANGEMENT; HEALTH CARE UTILIZATION; HUMAN; HYPEREOSINOPHILIA; KIDNEY CARCINOMA; LIVER CELL CARCINOMA; LUNG NON SMALL CELL CANCER; MALIGNANT NEOPLASTIC DISEASE; MYELODYSPLASTIC SYNDROME; MYELOPROLIFERATIVE DISORDER; ONCOLOGY; PANCREAS CANCER; PANCREATIC NEUROENDOCRINE TUMOR; PDGFR GENE; PHILADELPHIA 1 CHROMOSOME; RETROSPECTIVE STUDY; SYSTEMIC MASTOCYTOSIS; TREATMENT INDICATION; TREND STUDY;

EID: 84865383022     PISSN: 19454481     EISSN: 21642494     Source Type: Journal    
DOI: None     Document Type: Article

References (10)

1. CVS Caremark Analysis of data from IMS Health; Buck Consultants; NHE; Credit Suisse-2011.
2. Siegel R, Naishadham D, Jemal A. Cancer Statistics, 2012. American Cancer Society. CA Cancer J Clin. 2012;62(1):10-29.
3. American Cancer Society. Cancer Facts & Figures 2012. Atlanta: American Cancer Society; 2012.
4. US Food and Drug Administration. FDA approves Gleevec for expanded use in patients with rare gastrointestinal cancer [press release]. January 31, 2012. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm289760.htm. Accessed February 1, 2012.
5. Moore S, Brandt ML. Adherence to Oral Therapies for Cancer: Helping Your Patients Stay on Course Toolkit. Oncology Nursing Society; Revised November 1, 2009.
6. Hede K. Increase in oral cancer drugs raises thorny issues for oncology practices. J Natl Cancer Inst. 2009;101(22):1534-1536.
7. Correia RJ. Oral Oncology therapies: specialty pharmacy's newest challenge. Spec Pharm Times. http://specialty.pharmacytimes.com/publications/specialtypharmacy-times/2011/May-2011/Oral-Oncology-Therapies-Specialty-Pharma-cys-Newest-Challenge-. Published May 2011. Accessed January 16, 2012.
8. DeCardenas R, Helfrich JS. Oral therapies and safety issues for oncology Practices. Oncol Issues. http://accc-cancer.org/oncology_issues/articles/marapr10/ MA10-DeCardenas.pdf. Published March/April 2010. Accessed January 17, 2012.
9. Nelson R. Oral oncology: new perspectives on the role of pharmacists. Spec Pharm Times. http://specialty.pharmacytimes.com/publications/specialty-pharmacytimes/2011/May-2011/Oral-Oncology-New-Perspectives-on-the-Role-of-Pharmacists. Published December 5, 2011. Accessed January 17, 2012.
10. Wapner J. Behind closed network doors: oral cancer drugs and the rise of specialty pharmacy. Oncol Bus Rev. http://www.oncbiz.com/documents/OBR_ mar08_SP.pdf. Published March 2008. Accessed January 17, 2012.